References: 1. Van Dijk, et al. eCM. 2021;41:756-73. 2. Duan, et al. eCM. 2019;37:60-73. 3. Van Dijk, et al. Clin Spine Surg. 2020;33(6):E276-E287.
*Results from in vivo laboratory testing may not be predictive of clinical experience in humans. For important safety and intended use information please visit kurosbio.com. †MagnetOs is not cleared by the FDA as an osteoinductive bone graft. ‡MagnetOs has been proven to generate more predictable fusions than two commercially available alternatives in an ovine model of posterolateral fusion.
MagnetOs and NeedleGrip are trademarks of Kuros Biosciences.